Drug repurposing in pancreatic ductal adenocarcinoma

Informazioni relative al progetto

REPANCAN

ID dell’accordo di sovvenzione: 891135

DOI 10.3030/891135

Progetto chiuso

Data della firma CE 24 Marzo 2020

Data di avvio 1 Luglio 2020

Data di completamento 30 Giugno 2022

Finanziato da

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Costo totale € 140 021,76

Contributo UE € 140 021,76

Coordinato da

INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE
Serbia

Pubblicazioni

Conference proceedings (11)

Potential anti-metastatic activity of Imidazoline I1 receptor agonists in pancreatic ductal adenocarcinoma.

Autori: Zivic K, Pavlovic M, Ostojic M, Srdic-Rajic T, Grahovac J.
Pubblicato in: Keystone Symposium “Precision Oncology: Translating Discovery to the Clinic”., 2021
Editore: Keystone Symposia

Imidazoline-1 receptor agonist reduces cytokine production of PDAC stellate cells

Autori: Živić K, Ostojić M , Pavlović M, Srdić-Rajić T, Grahovac J.
Pubblicato in: EACR2022 Annual congress abstract book, 2022
Editore: EACR

Nischarin agonist rilmenidine inhibits pancreatic ductal adenocarcinoma cell migration and invasion

Autori: Marijana Pavlovic, Marija Ostojic, Kristina Zivic, Aleksandar Pavic, Tatjana Srdic-Rajic, Jelena Grahovac
Pubblicato in: Cancer Research, Numero Volume 82 12_Supplement, 2022, Pagina/e 3463-3463
Editore: The American Association for Cancer Research
DOI: 10.1158/1538-7445.am2022-3463

Rilmenidine binds to and inhibits the activity of MDR pumps in pancreatic ductal adenocarcinoma

Autori: Ostojić M, Đurić A, Srdić-Rajić T, Dobričić V, Grahovac J.
Pubblicato in: 5th Annual meeting of the CA17104 Abstract book, 2022
Editore: University of Coimbra

Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing

Autori: Jelena Grahovac, Marijana Pavlovic, Marija Ostojic, Kristina Zivic, Daniel Galun and Tatjana Srdic-Rajic
Pubblicato in: Cancer Research, Numero Volume 81 22_Supplement, 2021
Editore: American Association for Cancer Research
DOI: 10.1158/1538-7445.panca21-po-040

Anti-migratory properties of Nischarin agonist rilmenidine in pancreatic ductal adenocarcinoma.

Autori: Živić K, Ostojić M, Pavlović M, Srdić-Rajić T, Grahovac J.
Pubblicato in: Proceedings of the Tenth Conference of the Serbian Biochemical Society, 2021, Pagina/e 192
Editore: Faculty of Chemistry, University of BElgrade

Nischarin as a target for drug repurposing in solid tumors.

Autori: Ostojic M, Pavlovic M, Zivic K, Srdic-Rajic T, Grahovac J
Pubblicato in: EACR2021 conference proceedings, 2021
Editore: EACR

I1 imidazoline receptor ligand inhibits P-glycoprotein efflux in pancreatic ductal adenocarcinoma cells

Autori: Ostojić M, Srdić-Rajić T, Pavlović M, Živić K, Grahovac J.
Pubblicato in: 5th Congress of SDIR: Translational potential of cancer research in Serbia Abstract book, 2021
Editore: SDIR

Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing

Autori: Jelena Grahovac
Pubblicato in: 5th annual meeting of the COST-1704 Abstract book, 2021
Editore: STRATAGEM

Drug repurposing in pancreatic ductal adenocarcinoma

Autori: Jelena Grahovac
Pubblicato in: 5th Congress of SDIR: Translational potential of cancer research in Serbia Abstract book, 2021, Pagina/e p6
Editore: SDIR

Potential anti-MDR effect of rilmenidine in pancreatic ductal adenocarcinoma.

Autori: Ostojić M, Srdić-Rajić T, Pavlović M, Živić K, Grahovac J
Pubblicato in: EACR Conference Goodbye Flat Biology: Next Generation Cancer Models Abstract book, 2021
Editore: EACR

Other (1)

Nischarin expression may have differing roles in male and female melanoma patients

Autori: Marija Ostojić, Marko Jevrić, Olivera Mitrović-Ajtić, Miljana Tanić, Milena Čavić, Tatjana Srdić-Rajić Jelena Grahovac
Pubblicato in: Research Square, 2022
Editore: Research Square
DOI: 10.21203/rs.3.rs-1576440/v2